Gordon Hoag

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Erik S.G. Stroes, John R. Guyton, Norman E. Lepor et al. · Journal of the American Heart Association · 2016 · 102 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

High Incidence of Significant Urinary Ascorbic Acid Concentrations in a West Coast Population—Implications for Routine Urinalysis

M L Brigden, David Edgell, Michelle McPherson et al. · Clinical Chemistry · 1992 · 81 citations

Life Sciences, Nutritional Sciences, Clinical Biochemistry +15

Astroblastoma revisited: A report of three cases

Gordon Hoag, Anders A. F. Sima, B. Rozdilsky · Acta Neuropathologica · 1986 · 40 citations

Medicine, Oncology, Pathology +10